VKTX Initiates Phase 1 Study
Viking Therapeutics initiates Phase 1 study to evaluate novel amylin receptor agonist VK3019 in healthy adults
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.